Executives fromTocagen Inc., CytomX Therapeutics Inc., Trillium Therapeutics Inc., Xencor Inc. and Poseida Therapeutics Inc. sat down with Scrip to discuss what it takes to get an immuno-oncology deal done, starting with technology that gives pharma something it doesn't have but needs to improve the efficacy and safety of existing immunotherapies.
Companies with technology ranging from monoclonal antibodies to chimeric antigen receptor T cell (CAR-T) therapies assembled for the discussion last...






